Kissei Pharmaceutical Co Ltd represents a commitment to improving global health through its values and corporate philosophy. The company focuses on research and development of innovative pharmaceutical products that contribute to the well-being of individuals and society. Kissei Pharmaceutical Co Ltd strives for excellence, integrity, and accountability in all aspects of its operations. With a strong emphasis on patient-centric healthcare solutions, Kissei Pharmaceutical Co Ltd aims to enhance the quality of life for patients worldwide. By promoting continuous innovation and sustainable practices, the company aims to be a trusted and respected leader in the global pharmaceutical industry.

Kissei Pharmaceutical Co Ltd is primarily present in Japan.

Kissei Pharmaceutical Co Ltd has achieved various significant milestones throughout its history. Some notable achievements include the development of Lopid, a drug used for lipid metabolism disorders, which gained worldwide recognition. Additionally, the company successfully launched Cravit, an anti-infective agent that became widely prescribed. Kissei Pharmaceutical Co Ltd's commitment to research and development has led to advancements in pharmaceutical technology, resulting in the release of innovative products. The company continues to expand its global presence through collaborations and strategic partnerships. Kissei Pharmaceutical Co Ltd's constant strive for excellence and dedication to improving healthcare has solidified its position as a leading pharmaceutical company.

Kissei Pharmaceutical Co Ltd is a renowned company with a rich history and background. Founded in 1946, it has evolved and thrived over the years to become a leading pharmaceutical organization based in Japan. Kissei Pharmaceutical focuses on the research, development, and distribution of innovative pharmaceutical products. With a strong commitment to improving healthcare, the company has expanded its global presence, establishing subsidiaries and partnerships worldwide. Kissei Pharmaceutical's dedication to scientific excellence and customer satisfaction has earned them a stellar reputation in the pharmaceutical industry. Their continuous efforts to enhance medical treatments and contribute to society have solidified their position as a trusted and respected healthcare company.

Kissei Pharmaceutical Co Ltd faces competition from various companies in the market. Some of its main competitors include Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Shionogi & Co., Ltd., and Eisai Co., Ltd. These companies operate in the pharmaceutical industry and offer similar products and services, posing a competitive challenge to Kissei Pharmaceutical Co Ltd. It is important for Kissei Pharmaceutical Co Ltd to continually innovate and deliver high-quality products to stay competitive in the market and retain its position among these industry rivals.

Kissei Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

The business model of Kissei Pharmaceutical Co Ltd revolves around the development, manufacturing, and marketing of pharmaceutical products. Kissei Pharmaceutical Co Ltd specializes in the research of innovative drugs and strives to improve the health and well-being of individuals through its high-quality and reliable medications. By focusing on various therapeutic areas such as urology, kidney diseases, diabetes, and oncology, Kissei Pharmaceutical Co Ltd aims to address critical medical needs and provide effective treatment options. The company's commitment to research and development, coupled with its strong marketing strategies, enables it to deliver innovative and reliable pharmaceutical solutions to a global consumer base.

Az Kissei Pharmaceutical Co P/E mutatója 13,34.

Az Kissei Pharmaceutical Co KUV 1,97.

Az AlleAktien Minőségi Score Kissei Pharmaceutical Co esetében 4/10.

A Kissei Pharmaceutical Co forgalma 75,58 milliárd JPY.

A(z) Kissei Pharmaceutical Co nyereség 11,16 milliárd JPY.

Kissei Pharmaceutical Co Ltd is a Japanese company that has been active in the pharmaceutical business since 1946. The company is headquartered in Matsumoto and has branches in Japan, the USA, and China. Kissei focuses on the development, manufacturing, and marketing of prescription drugs, OTC products, and diagnostics. The three main business divisions of Kissei are the pharmaceutical division, the diagnostics division, and the health and care products division. Within the pharmaceutical division, the company develops and produces a wide range of prescription drugs for the treatment of conditions such as diabetes, pain, allergies, and asthma. Some of the key products of Kissei include: • Avigan: An antiviral medication used for the treatment of influenza and other viral infections. It was also used for the treatment of COVID-19 in 2020. • Fentiazac: An analgesic and anti-inflammatory medication used for the relief of pain in arthritis, inflammation, and injuries. • Glufast: An orally administered medication used for the treatment of type 2 diabetes mellitus. • Sarpul: An antihistamine used for the treatment of allergy symptoms. In the diagnostics division, Kissei offers a wide range of medical diagnostics products, such as immunassays, enzyme immunoassays, DNA tests, and antibody tests. These products are used in medical research and diagnostics. In the health and care products division, Kissei develops and produces a variety of products that promote well-being and health. These include dietary supplements, food, and beverages tailored to the needs of specific population groups (such as the elderly or athletes). Kissei also offers cosmetics tailored to the needs of the skin. Kissei's business model is based on creating value for its customers, shareholders, and employees. The company focuses on research and development to develop innovative products that meet the needs of patients and customers. Kissei works closely with university research institutions and other companies. The company places great importance on compliance with ethical and compliance principles, as well as ensuring the quality and safety of its products. Kissei strives to minimize its environmental impact and promote sustainable business practices. Additionally, the company is committed to responsible corporate governance. Overall, Kissei Pharmaceutical Co Ltd is a globally operating company with a wide portfolio of products and services in the pharmaceutical, diagnostics, and health and care products sectors. The company is dedicated to developing innovative solutions that contribute to the improvement of health and well-being.

A(z) Kissei Pharmaceutical Co évente alkalommal oszt ki 68,00 JPY összegű osztalékot.

A Kissei Pharmaceutical Co esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Kissei Pharmaceutical Co ISIN kódja: JP3240600001.

A Kissei Pharmaceutical Co WKN-je 881370.

Az Kissei Pharmaceutical Co tőzsdei rövidítése 4547.T.

Az elmúlt 12 hónapban a(z) Kissei Pharmaceutical Co osztalékot fizetett 86,00 JPY összegben. Ez körülbelül 2,61 % osztalékhozamnak felel meg. A következő 12 hóban a(z) Kissei Pharmaceutical Co várhatóan 89,31 JPY összegű osztalékot fog fizetni.

A(z) Kissei Pharmaceutical Co jelenlegi osztalékhozama 2,61 %.

A(z) Kissei Pharmaceutical Co negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: október, május, október, május.

A Kissei Pharmaceutical Co az elmúlt 23 évben minden évben fizetett osztalékot.

A következő 12 hónapban 89,31 JPY összegű osztalékra számítanak. Ez 2,71 % osztalékhozamnak felel meg.

A(z) Kissei Pharmaceutical Co a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Kissei Pharmaceutical Co által 2024. 12. 01.-án/én fizetett 45 JPY összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 09. 27.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 12. 01. időpontban történt.

2023 évben a Kissei Pharmaceutical Co 81 JPY összegű osztalékot fizetett ki.

Az Kissei Pharmaceutical Co osztalékait JPY fizeti ki.